Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Sees Strong Trading Volume – Still a Buy?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) shares saw unusually-high trading volume on Wednesday . Approximately 31,853 shares were traded during mid-day trading, a decline of 36% from the previous session’s volume of 49,568 shares.The stock last traded at $14.2550 and had previously closed at $14.80.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ARMP shares. HC Wainwright boosted their price objective on Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. JonesTrading started coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They set a “buy” rating and a $15.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $15.00.

Armata Pharmaceuticals Price Performance

The firm has a 50 day simple moving average of $10.48 and a 200-day simple moving average of $7.58. The company has a market cap of $495.60 million, a price-to-earnings ratio of -2.81 and a beta of 1.38.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its earnings results on Tuesday, March 31st. The company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($3.23). The business had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.74 million.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARMP. Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals during the fourth quarter worth $108,000. Millennium Management LLC acquired a new position in Armata Pharmaceuticals during the fourth quarter worth $164,000. OMERS ADMINISTRATION Corp acquired a new position in Armata Pharmaceuticals during the fourth quarter worth $177,000. SeaCrest Wealth Management LLC lifted its stake in Armata Pharmaceuticals by 17.3% during the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after purchasing an additional 6,034 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in Armata Pharmaceuticals during the fourth quarter worth $284,000. Institutional investors and hedge funds own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.